Evidence map›Paper›PMID 30891858›Full record

ArticlePediatric diabetes2019

Associations of HbA1c with the timing of C-peptide responses during the oral glucose tolerance test at the diagnosis of type 1 diabetes.

Heba M Ismail, Carmella Evans-Molina, Linda A DiMeglio, Dorothy J Becker, Ingrid Libman, Emily K Sims, David Boulware, Kevan C Herold, Lisa Rafkin, Jay Skyler and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Pediatric diabetes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Heba M IsmailDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0000-0003-0102-0030
Carmella Evans-MolinaDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0000-0001-7764-8663
Linda A DiMeglioDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0000-0002-8033-6078
Dorothy J BeckerDivision of Endocrinology and Metabolism, University of Pittsburgh and Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania.
Ingrid LibmanDivision of Endocrinology and Metabolism, University of Pittsburgh and Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania.
Emily K SimsDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana.
David BoulwareDepartment of Bio-statistics, H. Lee Moffitt Cancer Center, Tampa, Florida.
Kevan C HeroldDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.
Lisa RafkinDivision of Endocrinology, Diabetes, and Metabolism, University of Miami, Miami, Florida.
Jay SkylerDivision of Endocrinology, Diabetes, and Metabolism, University of Miami, Miami, Florida.
Mario A ClevesDepartment of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, Florida.
Jerry PalmerDepartment of Medicine, VA Puget Sound Health Care System, Seattle, Washington.
Jay M SosenkoDivision of Endocrinology, Diabetes, and Metabolism, University of Miami, Miami, Florida.ORCID 0000-0002-7204-8367
Type 1 Diabetes Trial Net and Diabetes Prevention Trial-Type-1 (DPT-1) Study Groups
Indiana University School of MedicineUniversity of Miami · USUniversity of Pittsburgh · USMoffitt Cancer Center · USUniversity of South Florida · USUniversity of Washington · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
Data Coordinating Center for Type 1 Diabetes TrialNet (UC4)USF: TrialNet UC4-3UC4DK117009 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2017 to 2019
$49.6M
Yale Diabetes Research CenterP30DK045735 · NIDDK · YALE UNIVERSITY · PI Richard A Flavell · 1993 to 2026
$44.0M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
NIDDK Type 1 Diabetes TrialNet Data Coordinating CenterUC4DK106993 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2015 to 2015
$36.6M
Translation CoreP30DK097512 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Carmella Evans-Molina · 2015 to 2026
$17.4M
Type 1 Diabetes TrialNet Clinical Network HubU01DK103282 · NIDDK · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI CARLA J GREENBAUM, KURT J GRIFFIN · 2014 to 2026
$14.2M
Northwest Clinical Center for Type 1 Diabetes - TrialNetU01DK061034 · NIDDK · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI GREENBAUM, CARLA J · 2001 to 2018
$10.3M
Type I Diabetes Trialnet at StsnfordU01DK061042 · NIDDK · STANFORD UNIVERSITY · PI WILSON, DARRELL M · 2001 to 2018
$8.5M
UCSF Trialnet: A Phase II Trial of Imatimib in New Onset Type I DiabetesU01DK061010 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GITELMAN, STEPHEN E · 2001 to 2018
$8.1M
Type 1 Diabetes-A Proposal for Prevention & InterventionU01DK085476 · NIDDK · UNIVERSITY OF MINNESOTA · PI MORAN, ANTOINETTE M. · 2009 to 2018
$7.1M
BLRD VA I01 BX001733NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA076292NIAID NIH HHSNIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK045735NIDDK NIH HHS P30 DK097512NIDDK NIH HHS R01 DK093954NIDDK NIH HHS U01 DK061010NIDDK NIH HHS U01 DK061034NIDDK NIH HHS U01 DK061042NIDDK NIH HHS U01 DK061058NIDDK NIH HHS U01 DK085461NIDDK NIH HHS U01 DK085465NIDDK NIH HHS U01 DK085466NIDDK NIH HHS U01 DK085476NIDDK NIH HHS U01 DK085499NIDDK NIH HHS U01 DK085509NIDDK NIH HHS U01 DK103153NIDDK NIH HHS U01 DK103180NIDDK NIH HHS U01 DK103266NIDDK NIH HHS U01 DK103282NIDDK NIH HHS U01 DK106984NIDDK NIH HHS U01 DK106994NIDDK NIH HHS U01 DK107013NIDDK NIH HHS U01 DK107014NIDDK NIH HHS UC4 DK106993NIDDK NIH HHS UC4 DK117009
6 · The paper itself

Abstract

backgroundIn new onset type 1 diabetes (T1D), overall C-peptide measures such as area under the curve (AUC) C-peptide and peak C-peptide are useful for estimating the extent of β-cell dysfunction, and for assessing responses to intervention therapy. However, measures of the timing of C-peptide responsiveness could have additional value.

objectivesWe assessed the contribution of the timing of C-peptide responsiveness during oral glucose tolerance tests (OGTTs) to hemoglobin A1c (HbA1c) variation at T1D diagnosis.

methodsWe analyzed data from 85 individuals <18 years with OGTTs and HbA1c measurements at diagnosis. Overall [AUC and peak C-peptide] and timing measures [30-0 minute C-peptide (early); 60 to 120 minute C-peptide sum-30 minutes (late); 120/30 C-peptide; time to peak C-peptide] were utilized.

resultsAt diagnosis, the mean (±SD) age was 11.2 ± 3.3 years, body mass index (BMI)-z was 0.4 ± 1.1, 51.0% were male. The average HbA1c was 43.54 ± 8.46 mmol/mol (6.1 ± 0.8%). HbA1c correlated inversely with the AUC C-peptide (P < 0.001), peak C-peptide (P < 0.001), early and late C-peptide responses (P < 0.001 each), and 120/30 C-peptide (P < 0.001). Those with a peak C-peptide occurring at ≤60 minutes had higher HbA1c values than those with peaks later (P = 0.003). HbA1c variance was better explained with timing measures added to regression models (R

conclusionsThese findings show that the addition of timing measures of C-peptide responsiveness better explains HbA1c variation at diagnosis than standard measures alone.

Indexed as

AdolescentAdultBlood GlucoseChildChild, PreschoolC-PeptideDiabetes Mellitus, Type 1FemaleGenetic Association StudiesGlucose Tolerance TestGlycated HemoglobinHumansInfantMaleMiddle AgedTime FactorsBlood GlucoseC-PeptideGlycated HemoglobinC-peptideglycemiaHbA1cOGTTtype 1 diabetes

Identifiers

PMID30891858
PMCPMC6655420
OpenAlexW2923463364

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.